Consistent Durable Responses Are Observed for Lifileucel in Melanoma Regardless of IL-2 Doses
Source: Targeted Oncology, March 2023
Findings from a post hoc analysis of the phase 2 C-144-01 trial (NCT02360579) suggest that regardless of the number of IL-2 doses administered, lifileucel (LN-144) delivered durable and objective responses in patients with advanced melanoma. These data were presented during the 2022 European Society for Medical Oncology Immuno-Oncology Congress.
In the overall population (n = 153), the objective response rate (ORR) for patients who received up to 6 doses of IL-2 following lifi leucel was 31.4% (95% CI, 24.1%-39.4%) by RECIST 1.1 criteria and independent review committee (IRC) assessment.1 Those who received 1 to 2 doses of IL-2 had a slightly higher ORR of 37.5% (95% CI, 15.2%-64.6%) vs those who received 3 to 4 doses (30.8%; 95% CI, 14.3%-51.8%) or 5 to 6 doses (31.2%; 95% CI, 22.7%-40.8%). However, there was no statistical signifi cant difference in ORR associated with the number of IL-2 doses received (P =.87).
Moreover, there was no significant difference in duration of response (DOR) by number of IL-2 doses received (P =.25). The median DOR was not reached (NR) in patients who received up to 6 IL-2 doses (95% CI, 8.3-NR), those administered 1 to 2 doses (95% CI, 2.7-NR), and those administered 3 to 4 doses (95% CI, 8.3-NR). In those who received 5 to 6 doses of IL-2, the median DOR was 24.6 months (95% CI, 4.1-NR).